PMID- 12866577
OWN - NLM
STAT- MEDLINE
DCOM- 20040310
LR  - 20141120
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 22
IP  - 2
DP  - 2003 Jun
TI  - HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial 
      carcinoma: correlation with oncoprotein expression and conventional pathological 
      parameters.
PG  - 265-71
AB  - The objective of the present study was to evaluate the correlation between HER-2 
      gene amplification and HER-2 protein overexpression in endometrial carcinoma 
      using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). 
      We also analyzed chromosome 17 aneusomy and the association between these 
      biological parameters and conventional clinicopathological variables. FISH 
      analysis was performed on 73 selected paraffin-embedded sections from endometrial 
      carcinomas which previously had HER-2 status determined immunohistochemically 
      using monoclonal antibodies (MoAb) 300G9 and CB11. Using a ratio of more than two 
      oncogene signals/centromere to indicate amplification, a total of 42 out of the 
      73 endometrial tumors included in this study resulted positive by FISH where as 
      protein overexpression was identified in 29 out of 73 with a concordance rate of 
      74.3%. However, when the mean signals/centromere per nucleus increased (ratio > 4 
      < or = 5) a higher concordance between the two assays was seen (p = 0.007). In 
      addition, HER-2 amplification was significantly correlated with tumor stage (p = 
      0.021) and myometrial invasion (p = 0.010), whereas chromosome 17 polisomy showed 
      a positive correlation only with myometrial invasion (p = 0.004) No significant 
      correlation was found between HER-2 gene amplification, chromosome 17 aneusomy 
      and patient outcome. Nevertheless, the probability of a 5 year overall survival 
      decreased from 70% to 43%, respectively, for ratio > 2 < or = 4 and ratio > 4 < 
      or = 5 when we grouped the amplified cases on the basis of HER-2:CEP17 ratio. In 
      conclusion, molecular characteristics provide objective data that may be useful 
      in predicting prognosis in patients with endometrial cancer.
FAU - Cianciulli, A M
AU  - Cianciulli AM
AD  - Dept. of Clinical Pathology, Regina Elena Cancer Institute, Rome, Italy. 
      cianciulli@ifo.it
FAU - Guadagni, F
AU  - Guadagni F
FAU - Marzano, R
AU  - Marzano R
FAU - Benevolo, M
AU  - Benevolo M
FAU - Merola, R
AU  - Merola R
FAU - Giannarelli, D
AU  - Giannarelli D
FAU - Marandino, F
AU  - Marandino F
FAU - Vocaturo, G
AU  - Vocaturo G
FAU - Mariani, L
AU  - Mariani L
FAU - Mottolese, M
AU  - Mottolese M
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antibodies, Monoclonal/metabolism
MH  - Carcinoma/*genetics
MH  - *Chromosomes, Human, Pair 17
MH  - Endometrial Neoplasms/*genetics/metabolism
MH  - Female
MH  - Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Myometrium/pathology
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Receptor, ErbB-2/biosynthesis
MH  - Time Factors
EDAT- 2003/07/18 05:00
MHDA- 2004/03/11 05:00
CRDT- 2003/07/18 05:00
PHST- 2003/07/18 05:00 [pubmed]
PHST- 2004/03/11 05:00 [medline]
PHST- 2003/07/18 05:00 [entrez]
PST - ppublish
SO  - J Exp Clin Cancer Res. 2003 Jun;22(2):265-71.